Alizyme plc
http://ww7.investorrelations.co.uk/alizyme/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alizyme plc
Takeda’s Andy Plump Tells The Japanese Pharma’s New Story
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Analyst Insight: Top 2021 Health Care Trends On Display At RSNA
A confluence of factors promoting the rapid adoption of health care AI is expected to make 2021 a pivotal year for the technology, as demonstrated by product launches at RSNA 2020.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Finance Watch: Biopharma VC Deals On Track For A Record-Breaking Year
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals